- Q4 2023 Immunocore Holdings PLC Earnings Call TranscriptFeb 28, 2024$69.21 (-1.76%)Earnings
- Immunocore Holdings PLC at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Immunocore Holdings PLC at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Immunocore Holdings PLC Earnings Call TranscriptAug 10, 2023$61.66 (-3.67%)Earnings
- Immunocore Holdings PLC at Goldman Sachs Healthcare Conference TranscriptJun 14, 2023
- Immunocore Holdings PLC at Bank of America Global Healthcare Conference TranscriptMay 11, 2023
- Immunocore Holdings PLC at Barclays Global Healthcare Conference TranscriptMar 15, 2023
- Q4 2022 Immunocore Holdings PLC Earnings Call TranscriptMar 01, 2023$54.05 (-1.46%)Earnings
- Immunocore Holdings PLC at Citi Virtual Oncology Leadership Summit TranscriptFeb 22, 2023
- Immunocore Holdings PLC at JPMorgan Healthcare Conference TranscriptJan 11, 2023
- Immunocore Holdings PLC at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Immunocore Holdings PLC at Jefferies London Healthcare Conference TranscriptNov 17, 2022
- Immunocore Holdings PLC PRAME Investor and Analyst Event AT ESMO 2022 TranscriptSep 09, 2022
- Q2 2022 Immunocore Holdings PLC Earnings Call TranscriptAug 10, 2022$53.95 (+4.27%)Earnings
- Immunocore Holdings PLC at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Immunocore Holdings PLC To Discuss FDA Approval Call TranscriptJan 26, 2022
Immunocore Holdings PLC at Citi Virtual Oncology Leadership Summit Transcript
So welcome back to our next session. My name is Andrew Baum, I run Global Healthcare here at Citi. Delighted to introduce an old friend, David Berman, David is Head of R&D at Immunocore, before that at Bristol-Myers Squibb and has touched many of the approved immuno-oncology drugs on the market over the years. It's good to have you. Also joined by Clay, who runs IR at Immunocore.
Now what I was going to do is unlike some of the majors, where many of you will be very familiar with the technology in hand because Immunocore developed and markets their own lead product, KIMMTRAK, many of you may be unfamiliar with the technology. So I was just going to hand over to David just to set a common denominator and differentiate the TCR-based approach with the bispecifics, which many of you will be familiar with, which address external antigens.
So David, good to have you here, and over to you for [the scene] setting.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)